Christopher Patusky's most recent trade in United Therapeutics Corp was a trade of 1,830 Stock Options done . Disclosure was reported to the exchange on July 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 1,830 | 1,830 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 650 | 650 | - | - | Restricted Stock Unit | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2025 | 590 | 1,490 (0%) | 0% | 0 | Common Stock | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2025 | 590 | 0 | - | - | Restricted Stock Unit | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 175.43 per share. | 19 Mar 2025 | 5,000 | 5,900 (0%) | 0% | 175.4 | 877,150 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2025 | 5,000 | 0 | - | - | Stock Option | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 308.82 per share. | 19 Mar 2025 | 1,780 | 3,820 (0%) | 0% | 308.8 | 549,701 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 313.14 per share. | 19 Mar 2025 | 1,299 | 1,000 (0%) | 0% | 313.1 | 406,769 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 312.22 per share. | 19 Mar 2025 | 736 | 2,299 (0%) | 0% | 312.2 | 229,792 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 310.80 per share. | 19 Mar 2025 | 457 | 3,035 (0%) | 0% | 310.8 | 142,035 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 309.73 per share. | 19 Mar 2025 | 328 | 3,492 (0%) | 0% | 309.7 | 101,591 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 307.73 per share. | 19 Mar 2025 | 300 | 5,600 (0%) | 0% | 307.7 | 92,320 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 313.77 per share. | 19 Mar 2025 | 100 | 900 (0%) | 0% | 313.8 | 31,377 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 5,000 | 5,000 | - | - | Stock Option | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 175.43 per share. | 10 Jan 2025 | 5,000 | 5,900 (0%) | 0% | 175.4 | 877,150 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 362.03 per share. | 10 Jan 2025 | 1,930 | 2,101 (0%) | 0% | 362.0 | 698,724 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 362.96 per share. | 10 Jan 2025 | 1,092 | 1,009 (0%) | 0% | 363.0 | 396,347 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 361.04 per share. | 10 Jan 2025 | 969 | 4,031 (0%) | 0% | 361.0 | 349,850 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 359.82 per share. | 10 Jan 2025 | 600 | 5,000 (0%) | 0% | 359.8 | 215,893 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 358.65 per share. | 10 Jan 2025 | 300 | 5,600 (0%) | 0% | 358.7 | 107,596 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 363.86 per share. | 10 Jan 2025 | 109 | 900 (0%) | 0% | 363.9 | 39,661 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 353.36 per share. | 03 Sep 2024 | 4,300 | 900 (0%) | 0% | 353.4 | 1,519,434 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 4,300 | 10,000 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 175.43 per share. | 03 Sep 2024 | 4,300 | 5,200 (0%) | 0% | 175.4 | 754,349 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 700 | 14,300 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 175.43 per share. | 03 Sep 2024 | 700 | 1,600 (0%) | 0% | 175.4 | 122,801 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 360.31 per share. | 03 Sep 2024 | 700 | 900 (0%) | 0% | 360.3 | 252,214 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2024 | 1,440 | 1,440 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2024 | 590 | 590 | - | - | Restricted Stock Unit | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2024 | 900 | 0 | - | - | Restricted Stock Unit | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2024 | 900 | 900 (0%) | 0% | 0 | Common Stock | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 295.50 per share. | 17 Jun 2024 | 2,000 | 0 (0%) | 0% | 295.5 | 591,000 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 2,000 | 3,000 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 76.36 per share. | 17 Jun 2024 | 2,000 | 2,000 (0%) | 0% | 76.4 | 152,720 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 264.35 per share. | 14 May 2024 | 1,310 | 0 (0%) | 0% | 264.4 | 346,299 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 1,310 | 5,000 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 76.26 per share. | 14 May 2024 | 1,310 | 1,310 (0%) | 0% | 76.3 | 99,901 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 224.00 per share. | 23 Feb 2024 | 1,680 | 4 (0%) | 0% | 224 | 376,320 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 2,280 | 2,280 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 900 | 900 | - | - | Restricted Stock Unit | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.03 per share. | 10 May 2023 | 2,000 | 3,684 (0%) | 0% | 88.0 | 176,060 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2023 | 2,000 | 4,000 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 212.24 per share. | 10 May 2023 | 2,000 | 1,684 (0%) | 0% | 212.2 | 424,480 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 217.50 per share. | 15 Mar 2023 | 2,000 | 1,680 (0%) | 0% | 217.5 | 435,000 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.03 per share. | 15 Mar 2023 | 2,000 | 3,680 (0%) | 0% | 88.0 | 176,060 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 2,000 | 6,000 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 273.32 per share. | 03 Jan 2023 | 2,000 | 1,680 (0%) | 0% | 273.3 | 546,640 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 2,000 | 8,000 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.03 per share. | 03 Jan 2023 | 2,000 | 3,680 (0%) | 0% | 88.0 | 176,060 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 261.05 per share. | 16 Nov 2022 | 1,500 | 1,680 (0%) | 0% | 261.1 | 391,575 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.03 per share. | 16 Nov 2022 | 1,500 | 3,180 (0%) | 0% | 88.0 | 132,045 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 1,500 | 10,000 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 262.61 per share. | 16 Nov 2022 | 100 | 1,100 (0%) | 0% | 262.6 | 26,261 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 1,500 | 11,500 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 1,500 | 0 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 221.63 per share. | 17 Aug 2022 | 1,500 | 1,680 (0%) | 0% | 221.6 | 332,445 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.03 per share. | 17 Aug 2022 | 1,500 | 3,180 (0%) | 0% | 88.0 | 132,045 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 221.63 per share. | 17 Aug 2022 | 1,500 | 1,680 (0%) | 0% | 221.6 | 332,445 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 17 Aug 2022 | 1,500 | 3,180 (0%) | 0% | 63.9 | 95,850 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 4,980 | 4,980 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 17 May 2022 | 2,000 | 3,680 (0%) | 0% | 63.9 | 127,800 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2022 | 2,000 | 1,500 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 190.99 per share. | 17 May 2022 | 2,000 | 1,680 (0%) | 0% | 191.0 | 381,980 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 190.11 per share. | 07 Apr 2022 | 2,000 | 1,680 (0%) | 0% | 190.1 | 380,220 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2022 | 2,000 | 3,500 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 07 Apr 2022 | 2,000 | 3,680 (0%) | 0% | 63.9 | 127,800 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 2,000 | 13,000 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 178.82 per share. | 15 Mar 2022 | 2,000 | 1,680 (0%) | 0% | 178.8 | 357,640 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.03 per share. | 15 Mar 2022 | 2,000 | 3,680 (0%) | 0% | 88.0 | 176,060 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 200.90 per share. | 11 Nov 2021 | 2,000 | 1,680 (0%) | 0% | 200.9 | 401,800 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 2,000 | 5,500 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 11 Nov 2021 | 2,000 | 3,680 (0%) | 0% | 63.9 | 127,800 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 200.16 per share. | 08 Nov 2021 | 2,300 | 1,680 (0%) | 0% | 200.2 | 460,368 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 206.09 per share. | 04 Aug 2021 | 2,000 | 3,980 (0%) | 0% | 206.1 | 412,180 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 04 Aug 2021 | 2,000 | 5,980 (0%) | 0% | 63.9 | 127,800 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 2,000 | 7,500 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 6,450 | 6,450 | - | - | Stock Options | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2021 | 1,680 | 0 | - | - | Restricted Stock Units | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2021 | 1,680 | 3,980 (0%) | 0% | 0 | Common Stock | |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 192.07 per share. | 06 May 2021 | 2,500 | 2,300 (0%) | 0% | 192.1 | 480,175 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2021 | 2,500 | 9,500 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 06 May 2021 | 2,500 | 4,800 (0%) | 0% | 63.9 | 159,750 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale of securities on an exchange or to another person at price $ 190.52 per share. | 06 May 2021 | 100 | 1,200 (0%) | 0% | 190.5 | 19,052 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Sale or transfer of securities back to the company at price $ 135.08 per share. | 08 Dec 2020 | 3,000 | 2,300 (0%) | 0% | 135.1 | 405,240 | Common Stock |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2020 | 3,000 | 12,000 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Christopher Patusky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.90 per share. | 08 Dec 2020 | 3,000 | 5,300 (0%) | 0% | 63.9 | 191,700 | Common Stock |